EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 365 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Dexrazoxane Protects the Heart Long Term for Kids Being Treated for... March 16, 2023 Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of... May 25, 2022 Mom Who Lost Child Donates Breast Milk To Mom With Cancer February 27, 2019 How CRISPR is Changing Cancer Research and Treatment July 27, 2020 Load more HOT NEWS The Nobel Prize winner helping us treat children’s cancers Tagraxofusp Proves Effective for BPDCN, A Rare Blood Cancer FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for NSCLC with EGFR... Increase in Node-Positive and Stage III Breast Cancer After Two Months...
